Vitrafy Reports 94% Post-Thaw Recovery in US Army Phase II Study

US Army Validates Vitrafy’s Cryopreservation Breakthrough

Vitrafy Life Sciences (ASX:VFY) has passed a crucial test in its quest to revolutionise platelet storage with the completion of a US Army Institute of Surgical Research (USAISR) Phase II study. The company’s proprietary cryopreservation ecosystem, particularly its no-wash 3% DMSO protocol, delivered an impressive 94% mean post-thaw platelet recovery, surpassing both traditional wash-based methods and trehalose-based alternatives. This performance not only exceeded established European and American regulatory benchmarks but also demonstrated superior clot strength and retention of critical platelet receptors.

This Phase II study, the largest of its kind conducted at commercial volumes, provides independent military validation that Vitrafy’s technology can reliably preserve platelets without the need for complex washing steps. The no-wash protocol removes logistical hurdles associated with centrifuge-based washing, which requires specialised equipment and trained personnel, making the technology a potential game changer for battlefield medicine, emergency response, and rural healthcare settings.

No-Wash Protocol Addresses Critical Market Gap

Currently, there are no FDA-approved cryopreserved platelet products on the US market, and existing platelet supplies are constrained by short shelf lives and demanding storage requirements. Vitrafy’s no-wash approach could unlock stockpiling and rapid deployment capabilities that have long eluded transfusion medicine. The technology’s ability to maintain near-fresh platelet quality post-thaw positions it to meet urgent needs in trauma care and remote medical facilities.

Dr Kristin Reddoch-Cardenas, the USAISR research lead, underscored the significance of these findings, highlighting the potential impact on both civilian and military trauma response. Vitrafy plans to publish the full Phase II results in peer-reviewed journals and present them at upcoming international scientific conferences, signalling growing recognition within the medical community.

Pathway to FDA Registration and Commercialisation

With Phase II validation complete, Vitrafy is advancing towards FDA medical device registration for its Guardion cryopreservation unit, targeting the first half of FY2027. Managing Director Brent Owens noted that these results bring the company closer to solving one of transfusion medicine’s most persistent logistical challenges. The company’s partnership with USAISR remains active, with ongoing collaboration expected to support regulatory submissions and market entry.

This milestone also aligns with Vitrafy’s strategic progress, including a recent no-wash platelet tech advancement that has accelerated commercial interest despite manufacturing delays. The company’s broader ecosystem integrates proprietary freezing hardware and cloud-based software, designed to maintain biomaterial integrity from collection through delivery.

Vitrafy’s success in this study builds on previous phases and reflects a growing momentum in its US military and civilian blood markets engagement. The company’s strategic partnerships and manufacturing scale-up efforts underpin its readiness for commercialisation, although market adoption timelines remain to be seen.